Molecular Diagnostics Market by Type, Technology, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2019-2023

Molecular Diagnostics Market Overview:

Global Molecular Diagnostics Market was valued at $5,962 million in 2016, and is expected to garner $10,557 million by 2023, registering a CAGR of 9.1% during the forecast period 2017-2023.

Molecular diagnostic tests are used to detect specific sequences in DNA or RNA, including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others to further diagnose the disease. These are cumulative techniques for analyzing biological markers at the molecular level, such as genome and proteome. These techniques are used for diagnosis of the various infectious diseases, cancer, and others and is also used to check the genetic predisposition to a disease.

The factors such increase in the prevalence of the infectious diseases and various types of cancer, increase in awareness and acceptance of personalized medicines, growth in the biomarker identification, and advancement in molecular diagnostics drive the market growth. Stringent regulatory requirements for the approval of new molecular diagnostics techniques hampers the growth of the market. However, increase in adoption of the molecular diagnostics in the emerging economies provide growth opportunities for the market.

Segment Review

The global molecular diagnostics market is segmented based on type, technology, application, end user, and geography. Based on type, it is classified into instruments, reagents, and software & services. The reagents segment contributed the highest share in 2016, owing to the rise in demand for solutions, quality control reagents, and different reagents for different tests. Based on technology, it is categorized into polymerase chain reaction (PCR), hybridization, DNA sequencing, microarray, isothermal nucleic acid amplification technology (INAAT), and others (electrophoresis, mass spectroscopy, and flow cytometry). PCR contributed to the highest share in 2016, owing to the increase in usage in proteomics and genomics, which is highly cost-effective. Based on application, it is divided into infectious diseases, oncology, genetic testing, blood screening, and others (Microbiology, neurological diseases, and cardiovascular diseases). Infectious diseases accounted for the highest market share in 2016, owing to the increase in the number of patients suffering from infectious diseases.

Based on end user, it is categorized into hospitals, reference laboratories, and others (blood banks, home health agencies, and nursing homes). Hospitals accounted for the highest market share in the global market in 2016, owing to the increase in the number of patients treated in hospitals.

Top Investment Pockets

The global molecular diagnostics market is segmented by application into infectious diseases, oncology, genetic testing, blood screening, and others (microbiology, neurological diseases, and cardiovascular diseases). Infectious diseases projected the highest revenue in 2016, with a CAGR of 9.3% for the forecast period of 2017-2023, owing to increase in the number of patients suffering from different viral and bacterial infections, such as Human Immunodeficiency Virus (HIV), Hepatitis C virus(HCV), Human Papillomavirus(HPV), Chlamydia trachomatis/ Neisseria gonorrhoeae (CT/NG), and others. Along with the improving healthcare facilities treating these diseases in the emerging nations.

Geographic Analysis

Geographically, the global molecular diagnostics market is segmented into North America, Europe, Asia-Pacific, and LAMEA. The North American molecular diagnostics market accounted for the highest market share in 2016, owing to the factors such as, large aging population, rise in number of cases of infectious and chronic diseases, and increase in awareness of personalized medicines. The European molecular diagnostics market is the second highest revenue generator, owing to well-penetrated healthcare system and favorable regulatory policies. The Asia-Pacific is expected to show the highest growth in the global molecular diagnostics market from 2017 to 2023, with an estimated CAGR of 10.1% owing to the improvement in healthcare facilities to treat the increasing patient population for infectious diseases and various types of cancer.

Key Benefits for Stakeholders

• The study provides an in-depth analysis of the global molecular diagnostics market and current trends and future estimations to elucidate the imminent investment pockets.
• The report provides a quantitative analysis of the industry from 2016 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the market based on type, technology, application, and end user elucidate various trends and prevailing opportunities across segments.
• Key market players operating in the market are profiled to determine the competitive outlook of the market by studying the different products of the companies and their developments.
• The key players profiled in the report include Abbott Laboratories, Inc., BioMrieux SA, Becton, Dickinson and Company, Cepheid (subsidiary of Danaher Corporation), Grifols, Hologic Corporation, Novartis AG, Qiagen N.V., Siemens Healthcare GmbH, and Roche Diagnostics.
• List of the other players (not included in the report) in the value chain includes Bayer Healthcare, Bio-Rad Laboratories, Johnson & Johnson, Dalko Diagnostics, and Sysmex Corporation.

Molecular Diagnostics Market Key Segments

CHAPTER 1 INTRODUCTION

1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. RESEARCH METHODOLOGY

1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1 Top winning strategies
3.2.2. Top investment pockets

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTERS FIVE FORCES ANALYSIS

3.4.1. Bargaining Power of Buyers
3.4.2. Bargaining Power of Suppliers
3.4.3. Threat of Substitution
3.4.4. Threat of New Entrants
3.4.5. Competitive Rivalry

3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in prevalence of infectious diseaseas and various types of cancer
3.5.1.2. Increase in awareness and acceptance of personalized medicines
3.5.1.3. Growth in biomarker identification market
3.5.1.4. Advancement in molecular diagnostics

3.5.2. Restrains

3.5.2.1. Stringent regulatory requirements for product approvals

3.5.3. Opportunity

3.5.3.1. High potential and increasing adoption of molecular diagnostics in emerging nations

CHAPTER 4 MOLECULAR DIAGNOSTICS MARKET, BY TYPE

4.1. OVERVIEW
4.2. INSTRUMENTS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. REAGENTS

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. SOFTWARE & SERVICES

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

5.1. OVERVIEW
5.2. INFECTIOUS DISEASES

5.2.1. Market size and forecast

5.3. ONCOLOGY

5.3.1. Market size and forecast

5.4. GENETIC TESTING

5.4.1. Market size and forecast

5.5. BLOOD SCREENING

5.5.1. Market size and forecast

5.6. OTHERS

5.6.1. Market size and forecast

CHAPTER 6 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

6.1. OVERVIEW
6.2. POLYMERASE CHAIN REACTION (PCR)

6.2.1. Market size and forecast

6.3. HYBRIDIZATION

6.3.1. Market size and forecast

6.4. DNA SEQUENCING

6.4.1. Market size and forecast

6.5. MICROARRAY

6.5.1. Market size and forecast

6.6. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)

6.6.1. Market size and forecast

6.7. OTHERS

6.7.1. Market size and forecast

CHAPTER 7 MOLECULAR DIAGNOSTICS MARKET, BY END USER

7.1. OVERVIEW
7.2. HOSPITALS

7.2.1. Market size and forecast

7.3. LABORATORIES

7.3.1. Market size and forecast

7.4. OTHERS

7.4.1. Market size and forecast

CHAPTER 8 MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
8.2.4. U.S.: market size and forecast
8.2.5. Canada: market size and forecast
8.2.6. Mexico: market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
8.3.4. Germany: market size and forecast
8.3.5. France market size and forecast
8.3.6. UK: market size and forecast
8.3.7. Italy: market size and forecast
8.3.8. Spain: market size and forecast
8.3.9. Rest of Europe: market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
8.4.4. Japan: market size and forecast
8.4.5. China market size and forecast
8.4.6. India: market size and forecast
8.4.7. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
8.5.4. Latin America: market size and forecast
8.5.5. Middle East market size and forecast
8.5.6. Africa: market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1. ABBOTT LABORATORIES, INC.

9.1.1. Overview
9.1.2. Operating business segments
9.1.3. Business performance
9.1.4. Key strategic moves & developments

9.2. BIOMRIEUX SA

9.2.1. Overview
9.2.2. Operating business segments
9.2.3. Business performance
9.2.4. Key strategic moves & developments

9.3. BECTON, DICKINSON AND COMPANY

9.3.1. Overview
9.3.2. Operating business segments
9.3.3. Business performance
9.3.4. Key strategic moves & developments

9.4. DANAHER CORP.

9.4.1. Overview
9.4.2. Operating business segments
9.4.3. Business performance
9.4.4. Key strategic moves & developments

9.5. GRIFOLS

9.5.1. Overview
9.5.2. Operating business segments
9.5.3. Business performance
9.5.4. Key strategic moves & developments

9.6. HOLOGIC INC.

9.6.1. Overview
9.6.2. Operating business segments
9.6.3. Business performance
9.6.4. Key strategic moves & developments

9.7. NOVARTIS AG

9.7.1. Overview
9.7.2. Operating business segments
9.7.3. Business performance
9.7.4. Key strategic moves & developments

9.8. ROCHE DIAGNOSTICS

9.8.1. Overview
9.8.2. Operating business segments
9.8.3. Business performance
9.8.4. Key strategic moves & developments

9.9. SIEMENS HEALTHCARE

9.9.1. Overview
9.9.2. Operating business segments
9.9.3. Business performance
9.9.4. Key strategic moves & developments

9.10. QIAGEN N.V.

9.10.1. Overview
9.10.2. Operating business segments
9.10.3. Business performance
9.10.4. Key strategic moves & developments

LIST OF TABLES

TABLE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 2. GLOBAL MOLECULAR DIAGNOSTIC INSTRUMENTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 3. GLOBAL MOLECULAR DIAGNOSTIC REAGENTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 4. GLOBAL MOLECULAR DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR ONCOLOGY, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR GENETIC TESTING, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SCREENING, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 11. MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 12. GLOBAL PCR MARKET FOR MOLECULAR DIAGNOSTICS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. GLOBAL HYBRIDIZATION MARKET FOR MOLECULAR DIAGNOSTICS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 14. GLOBAL DNA SEQUENCING MARKET FOR MOLECULAR DIAGNOSTICS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. GLOBAL MICROARRAY MARKET FOR MOLECULAR DIAGNOSTICS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 16. GLOBAL INAAT MARKET FOR MOLECULAR DIAGNOSTICS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 17. GLOBAL OTHER TECHNIQUES MARKET FOR MOLECULAR DIAGNOSTICS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 18. MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR LABORATORIES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 27. NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 28. EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 29. EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 30. EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 31. EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 32. EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023($MILLION)
TABLE 34. ASIA-PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 35. ASIA-PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 36. ASIA-PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. ASIA-PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 38. LAMEA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2016-2023($MILLION)
TABLE 39. LAMEA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 40. LAMEA: MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 41. LAMEA: MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42. LAMEA: MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 43. ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 44. ABBOTT LABORATORIES, INC.: BUSINESS SEGMENTS
TABLE 45 BIOMRIEUX SA: COMPANY SNAPSHOT
TABLE 46 BIOMRIEUX SA: BUSINESS SEGMENTS
TABLE 47 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 48 BECTON, DICKINSON AND COMPANY: BUSINESS SEGMENTS
TABLE 49 DANAHER CORP.: COMPANY SNAPSHOT
TABLE 50 DANAHER CORP.: BUSINESS SEGMENTS
TABLE 51 GRIFOLS: COMPANY SNAPSHOT
TABLE 52 GRIFOLS: BUSINESS SEGMENTS
TABLE 53 HOLOGIC INC.: COMPANY SNAPSHOT
TABLE 54 HOLOGIC INC.: BUSINESS SEGMENTS
TABLE 55 NOVARTIS AG: COMPANY SNAPSHOT
TABLE 56 NOVARTIS AG: BUSINESS SEGMENTS
TABLE 57 ROCHE DIAGNOSTICS LIMITED: COMPANY SNAPSHOT
TABLE 58 ROCHE DIAGNOSTICS LIMITED: BUSINESS SEGMENTS
TABLE 59 SIEMENS AG: COMPANY SNAPSHOT
TABLE 60 SIEMENS AG: BUSINESS SEGMENTS
TABLE 61 QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 62 QIAGEN N.V.: BUSINESS SEGMENTS

LIST OF FIGURES

FIGURE 1. MOLECULAR DIAGNOSTICS: MARKET SEGMENTATION
FIGURE 2. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
FIGURE 3. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 4. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 5. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 6. TOP INVESTMENT POCKETS: MOLECULAR DIAGNOSTICS MARKET
FIGURE 7. MARKET SHARE ANALYSIS: MOLECULAR DIAGNOSTICS MARKET, 2016
FIGURE 8. U.S.: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 9. CANADA: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 10. MEXICO: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 11. GERMANY: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 12. FRANCE: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 13. UK: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 14. ITALY: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 15. SPAIN: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 16. REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 17. JAPAN: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18. CHINA: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 19. INDIA: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 20. REST OF ASIA-PACIFIC: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 21. LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 22. MIDDLE EAST: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 23. AFRICA: MOLECULAR DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 24. ABBOTT LABORATORIES, INC. - TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 25. ABBOTT LABORATORIES, INC. - REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 26. ABBOTT LABORATORIES, INC. - REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 27. BIOMRIEUX SA- TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 28. BIOMRIEUX SA - REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 29. BIOMRIEUX SA - REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 30. BECTON, DICKINSON, AND COMPANY - TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 31. BECTON, DICKINSON, AND COMPANY - REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 32. BECTON, DICKINSON, AND COMPANY - REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 33. DANAHER CORP. - TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 34. DANAHER CORP. - REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 35. DANAHER CORP. - REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 36. GRIFOLS -TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 37. GRIFOLS - REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 38. GRIFOLS -REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 39. HOLOGIC INC. - TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 40. HOLOGIC INC. - REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 41. HOLOGIC INC.: REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 42. NOVARTIS AG- TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 43. NOVARTIS AG- REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 44. NOVARTIS AG: REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 45. ROCHE DIAGNOSTICS - TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 46. ROCHE DIAGNOSTICS - REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 47. ROCHE DIAGNOSTICS: REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 48. SIEMENS HEALTHCARE GMBH- TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 49. SIEMENS HEALTHCARE GMBH- REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 50. SIEMENS HEALTHCARE GMBH: REVENUE, BY GEOGRAPHY, 2016 (%)
FIGURE 51. QIAGEN N.V.- TOTAL REVENUE, 2014-2016 ($MILLION)
FIGURE 52. QIAGEN N.V.- REVENUE, BY PRODUCT CATEGORY, 2016 (%)
FIGURE 53. QIAGEN N.V.: REVENUE, BY GEOGRAPHY, 2016 (%)